Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament storage and delivery devices

a technology of storage and delivery device and medicine, which is applied in the direction of microcapsules, pharmaceutical packaging, packaging, etc., can solve the problems of adversely affecting the release, stability and bioavailability of active ingredients, and the dispensing and administration of solid dosage forms are not without associated problems and drawbacks

Inactive Publication Date: 2005-09-22
PHARMAKODEX LTD
View PDF12 Cites 57 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a delivery device for medicament that can be administered to a patient through the oral cavity. The device includes a sachet pack with multiple unit doses of the medicament enclosed between two strips. The device also includes an actuator that can separate the two strips to release the medicament. The device has a mouthpiece with an opening that allows the medicament to pass through. The actuator can be a roller or a gear that causes a predetermined rotation of the strips, which in turn causes the medicament to be released from the sachet pack. The device can be used to treat various medical conditions."

Problems solved by technology

However, the manufacture, dispensing and administration of solid dosage forms are not without associated problems and drawbacks.
However, these added excipients have been shown to adversely influence the release, stability and bioavailability of the active ingredient.
The added excipients are a particular problem with drugs that require a high dose in order to provide a therapeutic effect, e.g., biphosphonate drugs.
The inclusion of the additional excipient can make the final tablet extremely large, which could result in esophogeal damage if the dosage form is not swallowed properly.
Further, the tableting of certain drugs has many associated production problems.
In particular, many drugs, e.g., acetaminophen, have poor compressibility and cannot be directly compressible into solid dosage forms.
Consequently, such drugs must either be wet granulated or manufactured in a special grade in order to be tableted which increases manufacturing steps and production costs.
Even strict adherence to these practices still is not a guarantee that acceptable variation will occur.
With the high cost of industrial scale production and governmental approval of solid dosage forms, such formulations are often available in a limited number of strengths, which only meet the needs of the largest sectors of the population.
Unfortunately, this practice leaves many patients without acceptable means of treatment and physicians in a quandary with respect to individualizing dosages to meet the clinical needs of their patients.
The dispensing of oral solid dosage forms also makes the formulations susceptible to degradation and contamination due to repackaging, improper storage and manual handling.
There are also many patients who are unable or unwilling to take conventional orally administered dosage forms.
For some patients, the perception of unacceptable taste or mouth feel of a dose of medicine leads to a gag reflex action that makes swallowing difficult or impossible.
Other patients, e.g., pediatric and geriatric patients, find it difficult to ingest typical solid oral dosage forms, e.g., due to tablet size.
Other patients, particularly elderly patients, have conditions such as achlorhydria, which hinders the successful use of oral solid dosage forms.
While liquid formulations are more easily administered to the problem patient, liquid / suspension formulations are not without their own significant problems and restrictions.
The liquid dose amount is not as easily controlled compared with tablet and capsule forms and many therapeutic agents are not sufficiently stable in solution / suspension form.
Indeed, most suspension type formulations are typically reconstituted by the pharmacist and then have a limited shelf life even under refrigerated conditions.
Another problem with liquid formulations, which is not as much a factor with tablets and capsules, is the taste of the active agent.
The taste of some therapeutic agents is so unacceptable that liquid formulations are not a viable option.
Further, solution / suspension type formulations are typically not acceptable where the active agent must be provided with a protective coating, e.g. a taste masking coating or an enteric coating to protect the active agent from the strongly acidic conditions of the stomach.
However, such formulations also have drawbacks such as decreased bioavailability of the drug due to improper administration by the patient.
For example, if a patient's breathing is not coordinated with the activation of the device, the active agent will not reach its intended site of action which will lead to a decrease in therapeutic benefit.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament storage and delivery devices
  • Medicament storage and delivery devices
  • Medicament storage and delivery devices

Examples

Experimental program
Comparison scheme
Effect test

first embodiment

[0066]FIG. 2 shows a perspective view of a drug delivery device 1000 in accordance with the present invention, and FIG. 3 shows an exploded perspective view of FIG. 2. Further details of the device 1000 are shown in FIGS. 4(a,b). Referring to FIG. 3, a drug delivery device 1000 includes a housing 100 comprised of a first body portion 1 and a second body portion 2. The sachet pack 170 described above is shown in further detail in FIG. 4(b). The sachet pack 170 is comprised of a plurality of individual sachets 17, and is stored within the housing 100. The sachet pack 170 is a continuous sheet which is comprised of a pair of strips 1701, 1702 which are adhered to each other and which enclose a medicament.

[0067] The device 1000 includes a chassis 3 having a pair of lead rollers 7.1, 7.2 (collectively, lead rollers 7), wherein roller 7.1 is offset forward and above with respect to roller 7.2 as shown in FIG. 3. A sachet drive mechanism 20, which is partially enclosed within a hollow inte...

second embodiment

[0077] the present invention (device 1000′) is illustrated in FIGS. 6-10, with similar components bearing similar reference numerals to FIGS. 1-5.

[0078] Referring to FIGS. 10(a)-10(d), in use, a patient moves cover 5′ first in a direction 21 (FIGS. 6 and 10(b)), and then in a direction 22 (FIGS. 6 and 10(c)) to expose the mouthpiece 4. Preferably, the cover 5′ can be secured on the rear of the housing 100′ as shown in FIG. 10(d). As the cover 5′ moves in the direction 22 (clockwise from the perspective in FIG. 6 and counterclockwise from the perspective in FIG. 10(b)), lever 5.1 turns cover hinge 9.21 clockwise (from the perspective of FIG. 6), thereby tensioning torsion spring 9.22, which, in turn, applies a clockwise force to gear 9.23.

[0079] As shown in FIGS. 6 and 9, actuator 14′ includes an index button 14.1′ which extends through opening 102 in housing 100′. Actuator 14′ further includes an arm 14.2 having a protrusion 14.3. Arm 14.2 extends between gear 9.1 and housing part ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
mean diameteraaaaaaaaaa
mean diameteraaaaaaaaaa
weight percentaaaaaaaaaa
Login to View More

Abstract

A multiple dose delivery device for delivering a medicament into an oral cavity of a patient is provided. The device includes a sachet pack including a plurality of unit doses of a medicament enclosed between a first strip and a second strip. The device further includes a sachet advance mechanism and a mouthpiece. Upon actuation by a user, the sachet advance mechanism, which is engaged with the sachet pack, separates the first strip from the second strip to release one of the plurality of the unit doses from the sachet pack. The mouthpiece includes an opening, and each released unit dose passes through the opening.

Description

[0001] This application claims priority from U.S. Provisional Application Nos. 60 / 362,307 filed on Mar. 07, 2002 and No. 60 / 366,710 filed Mar. 22, 2002, the entire disclosures of which are hereby incorporated by reference.BACKGROUND OF THE INVENTION [0002] The most prominent mode of delivery of therapeutic agents is by the oral route by means of solid dosage forms such as tablets and capsules. Oral administration of solid dosage forms is more convenient and accepted than other modes of administration, e.g. parenteral administration. However, the manufacture, dispensing and administration of solid dosage forms are not without associated problems and drawbacks. [0003] With the manufacture of solid dosage forms, in addition to the active agent, it is necessary to combine other ingredients in the formulations for various reasons, such as to enhance physical appearance, to provide necessary bulk for tableting or capsuling, to improve stability, to improve compressibility or to aid in dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61J1/03A61J7/00A61J7/02A61J3/06A61K9/00A61K9/14A61K9/16A61K9/30A61K9/50A61K31/165A61K31/167A61K31/341A61K31/4045A61K31/44A61K31/4402A61K31/454A61K31/661A61K47/10A61K47/26A61K47/32A61K47/34A61K47/36A61K47/42
CPCA61J1/03A61J3/005A61J7/0076A61K9/0007A61K9/0056A61K9/1617A61K9/1623A61K9/5047A61K9/5073A61K9/5078A61K31/165A61K31/167A61K31/341A61K31/4045A61K31/44A61K31/4402A61K31/454A61K31/661A61J7/0061
Inventor STANIFORTH, JOHN NICHOLASTOBYN, MICHAELBOWMAN, NICHOLAS JOHNWRIGHT, MATTHEWHOWARD, GARY STEPHENBROOK SIMPSON, DAVID BADLEY
Owner PHARMAKODEX LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products